Fujifilm Holdings America Corporation

09/15/2025 | Press release | Distributed by Public on 09/15/2025 07:20

FUJIFILM Biosciences Introduces BalanCD HEK293 Perfusion A Medium to Enable Gene Therapy Production

  • First commercially available cell culture solution for HEK293 cells and perfusion - optimized for high cell density (HCD), intensified processes and perfusion cultures
  • Additional capabilities for continuous Adeno-Associated Virus (AAV) and Lentivirus (LV) production for consistent quality, performance, and scalability

SANTA ANA, California, Sept. 15, 2025 - FUJIFILM Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the Life Science market, today announced the commercial launch of BalanCD HEK293 Perfusion A. Designed to expand and augment the company's portfolio of gene therapy application solutions, BalanCD HEK293 Perfusion A uses suspension HEK293 cells and perfusion technology to provide reliable, efficient, and scalable production of viral vectors for development of gene therapies.

HEK293 cells are well established for gene therapy applications in upstream bioprocessing, offering reliable growth rates, high transfection success and expression of cellular factors needed for virus replication. BalanCD HEK293 Perfusion A further enables process optimization by maximizing cell growth, viability, and productivity, and supporting a wide range of applications including viral vector production, transient protein expression, and recombinant protein production.

This medium is designed for high density perfusion culture with demonstrated compatibility across a variety of cell retention devices giving it broad versatility across workflows, and is available in a variety of media package options for continuous processing and optimal performance. The BalanCD HEK293 Perfusion A medium is compatible with different types of transfection methods, and suited for both steady-state and intensified perfusion processes.

The new product harnesses the benefits of perfusion technology to enable a reduction in overall capital expenditures associated with AAV and LV production - key virus types for in vivo and in vitro gene transfer. Together, it can help maximize resources for consistency and scalability while providing clinical-quality, high-performing media that can support large-scale commercial batch sizes for advanced therapy development.

"FUJIFILM Biosciences is committed to helping our partners bring innovative new treatments and therapies to more patients than ever before. With BalanCD HEK293 Perfusion A medium, we have introduced a new way to advance gene therapies, building on a family of purposely-designed, high performing HEK293 products to provide more consistent, high-quality resources across the treatment spectrum," said Erik Vaessen, chief business officer, FUJIFILM Biosciences. "This innovative approach is another example on how we are customizing services, products, and systems to help all who bring therapeutics to more patients, as we continue to work on this mission together."

For more information about FUJIFILM Biosciences' BalanCD HEK293 Perfusion A medium and the entire BalanCD HEK293 product portfolio, please visit fujifilmbiosciences.fujifilm.com

ENDS

For high-res images, please contact [email protected]

FUJIFILM Biosciences

With a foundation in cell culture that dates back to 1970, FUJIFILM Biosciences is a global, full spectrum supplier to the life sciences market, providing products and services that assist customers in advancing healthcare initiatives. With an expanding portfolio of applications supported that include life science and discovery research, cell and gene therapy, as well as the large-scale production of biotherapeutics and vaccines, the Company is trusted by researchers and manufacturers worldwide. For over 50 years, FUJIFILM Biosciences' Mission has been to empower all who bring medicines and treatments to life with unmatched quality and responsiveness in its products and custom solutions, providing customers with the vital resources needed to enrich human lives through innovative, accessible therapies. The Company's facilities adhere to both ISO and FDA regulations, with manufacturing facilities that follow cGMP guidelines in the USA, Japan, and the Netherlands, and a media optimization center in China. All sites prioritize strategies that adhere to the FUJIFILM Sustainability Value Plan 2030 for sustainable growth. FUJIFILM Biosciences is a subsidiary of FUJIFILM Holdings America Corporation reporting to FUJIFILM Holdings Corporation.

For more information, please visit: fujifilmbiosciences.fujifilm.com

FUJIFILM Holdings Corporation

FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of "giving our world more smiles," we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: https://holdings.fujifilm.com/en.

For further details about our commitment to sustainability and Fujifilm's Sustainable Value Plan 2030, click here.

Media Contact:

Lori Serles FUJIFILM [email protected] (949) 261-7800 x145

Lily Jeffery Zyme [email protected] +44 (0)7891 477 378

Back to List
Fujifilm Holdings America Corporation published this content on September 15, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 15, 2025 at 13:20 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]